Home-based Cardiovascular Rehabilitation in Young Patients With Congenital Heart Disease: the "Muscle Your Heart" Program

NCT ID: NCT07115589

Last Updated: 2025-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Standard cardiovascular rehabilitation is performed in a medical care and rehabilitation centre. However, it may not be adapted to the patient's profile and there are few medical care and rehabilitation centres specialized in pediatric cardiology. The objective of this study is to evaluate the impact of cardiovascular rehabilitation entirely at home on the physical fitness of young patients with congenital heart disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Young patients with congenital heart disease suffer from physical deconditioning \[1\], negatively impacting the quality of life \[2, 3\], due in particular to obstacles stated by the patient's social environment \[4, 5\]. For this, there is cardiovascular rehabilitation, however, it may not be adapted to the patient's profile and there are few specialized centres in France. In the sense, the QUALIREHAB program, tested in a randomized controlled trial, was created. This 3-month hybrid program (at the patient's home and in a medical care and rehabilitation centre), combining adapted physical activity, patient therapeutic education and psychosocial support, has demonstrated positive effects on quality of life, level of physical activity, knowledge of the disease, body mass index and mental health \[6\].

However, this program has limitations, including the need for a medical care and rehabilitation centre near the patient's home.

This study, evaluating the impact of a 3-month cardiovascular rehabilitation program entirely at home, will improve this program by taking into account its limitations and will apply it to real life, without all the human, financial and material resources of a randomized controlled trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CHD - Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fully home-based cardiovascular rehabilitation program

3-month cardiovascular rehabilitation program entirely at home, combining adapted physical activity, therapeutic education and psychosocial support

Group Type EXPERIMENTAL

Muscle Your Heart home-based program

Intervention Type OTHER

2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Muscle Your Heart home-based program

2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Indication for home cardiovascular rehabilitation given by the referring cardiologist as part of routine care.
* Follow-up for congenital heart disease in the ACC-CHD classification.
* Patient aged 8 to 25 years at the time of inclusion.
* Consent of the adult patient or the parents or legal guardians of the minor patient.
* Social security affiliation (excluding AME).
* VO2max and/or SV1 \< -1.64 z-score for patients aged 8 to 17 years or VO2max \< 80% and/or SV1 \< 55% of theoretical VO2max for patients aged 18 to 25 years

Exclusion Criteria

* Unstable and/or severe heart failure: severe heart failure (NYHA functional class IV), recent decompensated heart failure requiring hospitalisation and/or any significant change in medication (\< 3 months before inclusion), systolic ventricle dysfunction (left ventricular or systemic ventricular ejection fraction \< 50%).
* Severe hypoxemia: pulse oxygen saturation (SpO2) at rest \< 85%, and/or SpO2 at exercise \< 80%, and/or patient requiring oxygen therapy.
* Pulmonary hypertension as defined by the 2020 ESC guidelines, whatever the aetiology.
* Significant systolic right ventricle (sRV) hypertension (Srv pressure \> 50% of systemic systolic pressure).
* Uncontrolled arrhythmia: symptomatic arrhythmia treated or untreated at rest and/or during exercise, treated arrhythmia with sustained supraventricular or ventricular tachycardia on ECG monitoring or during exercise and/or CPET, occurrence or aggravation of any supraventricular or ventricular arrhythmia during exercise and/or CPET.
* Advanced atrioventricular block (degree 2 or 3), occurrence or aggravation of any conduction disorder during exercise and/or CPET.
* Uncontrolled arterial hypertension at rest (blood pressure at rest during the consultation \> 140/90 mmHg in adults, \> 95th percentile in children).
* Acute or recent myocarditis and pericarditis (\< 3 months).
* Symptomatic aortic or subaortic stenosis (mean gradient \> 50 mmHg).
* Non-corrected coarctation of the aorta (surgical or catheter-based repair) with a clinical systolic gradient \> 20 mmHg.
* Dilatation of the aorta (aortic root \> 40 mm in adults, \> 2 z-score in children) (http://www.parameterz.com/sites/aortic-root) except in the case of repaired CHD with dilatation of the aorta inherent in the malformation and without risk of aortic dissection (tetralogy of Fallot, transposition of the great vessels, pulmonary atresia IVC, common trunk artery).
* Severe obstructive hypertrophic cardiomyopathy.
* Acute systemic disease.
* Recent intracardiac thrombus (\< 3 months), embolism or thrombophlebitis.
* Inability to follow instructions and/or home rehabilitation and/or answer questionnaires, as determined by the investigator.
* Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and patients with mental impairment leading to inability to cooperate.
* Inability to undergo the physical intervention: inability to physically exercise, any invasive medical intervention occurring within 6 months preceding the inclusion or scheduled during the 3-month study period (such as cardiac surgery, catheter-based intervention, orthopedic surgery, chemotherapy for cancer, or any other significant medical treatment or intervention, as determined by the investigator).
* For female patients: pregnancy, planning to become pregnant, or breastfeeding woman following questioning of the patient.
* Any other clinical and/or pharmacological treatment that is believed to interfere with the study or the optimal clinical care.
* Patients deprived of their liberty due to ongoing legal procedure, adult patients under guardianship or curatorship, or unable to personally express their consent.
* Patients who have benefited from cardiovascular rehabilitation in the 12 months preceding inclusion.
* Patient participating or wishing to participate in any interventional clinical research (drug trial, medical device, non-drug trial).
Minimum Eligible Age

8 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bordeaux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pr Pascal AMEDRO, MD,PhD

Role: STUDY_DIRECTOR

CHU de Bordeaux - Hôpital Cardiologique Haut Lévêque

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Bordeaux - Hôpital Cardiologique Haut Lévêque

Pessac, France, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pr Pascal AMEDRO, MD,PhD

Role: CONTACT

5 57 65 61 09 ext. 33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pr Pascal AMEDRO, MD,PhD

Role: primary

5 57 65 61 09 ext. 33

Related Links

Access external resources that provide additional context or updates about the study.

https://doi.org/10.1136/heartjnl-2017-312339

Amedro, P., Gavotto, A., Guillaumont, S., Bertet, H., Vincenti, M., De La Villeon, G., et al. (2018). Cardiopulmonary fitness in children with congenital heart diseases versus healthy children. Heart (British Cardiac Society), 104(12), 1026-1036.

https://doi.org/10.1007/s00246-015-1201-x

Amedro, P., Dorka, R., Moniotte, S., Guillaumont, S., Fraisse, A., Kreitmann, B., et al. (2015). Quality of Life of Children with Congenital Heart Diseases: A Multicenter Controlled Cross-Sectional Study. Pediatric cardiology, 36(8), 1588-1601.

https://doi.org/10.1016/j.ijcard.2015.11.028

Amedro, P., Picot, M. C., Moniotte, S., Dorka, R., Bertet, H., Guillaumont, S., et al. (2016). Correlation between cardio-pulmonary exercise test variables and health-related quality of life among children with congenital heart diseases. International

https://doi.org/10.1016/j.ahj.2009.02.014

Longmuir, P. E., \& McCrindle, B. W. (2009). Physical activity restrictions for children after the Fontan operation: disagreement between parent, cardiologist, and medical record reports. American heart journal, 157(5), 853-859

https://doi.org/10.1136/heart.83.6.685

Swan, L., \& Hillis, W. S. (2000). Exercise prescription in adults with congenital heart disease: a long way to go. Heart (British Cardiac Society), 83(6), 685-687

https://doi.org/10.1249/01.MSS.0000078924.61453.FB

Craig, C. L., Marshall, A. L., Sjöström, M., Bauman, A. E., Booth, M. L., Ainsworth, B. E., Pratt, M., et al. (2003). International physical activity questionnaire: 12-country reliability and validity. Medicine and science in sports and exercise, 35(8

https://doi.org/10.1079/phn2005898

Hagströmer, M., Oja, P., \& Sjöström, M. (2006). The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public health nutrition, 9(6), 755-762

https://doi.org/10.1007/s00431-009-1010-4

Wind, A. E., Takken, T., Helders, P. J., \& Engelbert, R. H. (2010). Is grip strength a predictor for total muscle strength in healthy children, adolescents, and young adults?. European journal of pediatrics, 169(3), 281-287

https://doi.org/10.1519/JSC.0b013e3181ddb03d

Castro-Piñero, J., Ortega, F. B., Artero, E. G., Girela-Rejón, M. J., Mora, J., Sjöström, M., \& Ruiz, J. R. (2010). Assessing muscular strength in youth: usefulness of standing long jump as a general index of muscular fitness. Journal of strength and

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A01806-41

Identifier Type: OTHER

Identifier Source: secondary_id

CHUBX 2024/23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.